Halozyme Therapeutics (HALO) EBT (2016 - 2025)
Historic EBT for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $219.0 million.
- Halozyme Therapeutics' EBT rose 3258.37% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $745.9 million, marking a year-over-year increase of 5537.36%. This contributed to the annual value of $557.1 million for FY2024, which is 5994.42% up from last year.
- Per Halozyme Therapeutics' latest filing, its EBT stood at $219.0 million for Q3 2025, which was up 3258.37% from $204.9 million recorded in Q2 2025.
- Halozyme Therapeutics' 5-year EBT high stood at $219.0 million for Q3 2025, and its period low was $28.1 million during Q1 2021.
- In the last 5 years, Halozyme Therapeutics' EBT had a median value of $93.2 million in 2023 and averaged $103.7 million.
- Its EBT has fluctuated over the past 5 years, first skyrocketed by 56103.09% in 2021, then crashed by 6720.68% in 2022.
- Over the past 5 years, Halozyme Therapeutics' EBT (Quarter) stood at $54.8 million in 2021, then rose by 29.16% to $70.8 million in 2022, then soared by 42.92% to $101.2 million in 2023, then surged by 76.14% to $178.2 million in 2024, then increased by 22.86% to $219.0 million in 2025.
- Its EBT was $219.0 million in Q3 2025, compared to $204.9 million in Q2 2025 and $143.8 million in Q1 2025.